Prosecution Insights
Last updated: October 04, 2026
Application No. 19/013,121

BIOLOGICAL DEVICES AND COMPOSITIONS FOR INCREASING HAIR GROWTH AND METHODS OF USE THEREOF

Final Rejection §112
Filed
Jan 08, 2025
Priority
Jan 11, 2024 — provisional 63/619,828
Examiner
STOICA, ELLY GERALD
Art Unit
Tech Center
Assignee
Bio Capital Holdings LLC
OA Round
2 (Final)
67%
Grant Probability
Favorable
3-4
OA Rounds
9m
Est. Remaining
89%
With Interview

Examiner Intelligence

Grants 67% — above average
67%
Career Allowance Rate
831 granted / 1242 resolved
+6.9% vs TC avg
Strong +22% interview lift
Without
With
+22.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 6m
Avg Prosecution
45 currently pending
Career history
1263
Total Applications
across all art units

Statute-Specific Performance

§101
4.0%
-36.0% vs TC avg
§103
28.9%
-11.1% vs TC avg
§102
15.1%
-24.9% vs TC avg
§112
36.2%
-3.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1242 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Amendment In the amendment filed on 08/19/2026, Applicant amended claim1 and cancelled claims 2-5, 12 and 14. Claims 1, 6-11, 13 and 15-30 are pending; claims 20-30 remain withdrawn from prosecution for being drawn to non-elected subject matter. Claims 1, 6- 11, 13 and 15-19 are examined. Maintained claim rejections Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1, 6-11, 13 and 16-19 remain rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement for reasons of record. On page 5-6 of the Remarks Applicant argues that: “Due to the typical level of skill in the art and the specific sequences and homologies in claim 1 as amended, Applicant respectfully submits the enablement requirement is satisfied.” The arguments were carefully considered but not found persuasive because, first of all, the rejection was a written description rejection (lack of possession of the broader claim). As already indicated in the Non-final rejection of 06/16/2026: “[T]he purpose of the written description requirement is to ‘ensure that the scope of the right to exclude, as set forth in the claims, does not overreach the scope of the inventor’s contribution to the field of art as described in the patent specification.’” Examiner never argued about enablement, but the fact that DNA constructs may comprise a vast number of arrangements of coding sequences for a set of four protein encoding sequences, further comprising promoters and terminators, the skilled artisan would not have been in possession of the vast repertoire of constructs encompassed by the claimed invention; one of skill in the art would conclude that applicant was not in possession of the structural attributes of a representative number of species possessed by the members of the genera of possible DNA constructs as claimed. The amended claim 1 provides 95% homology requirements for each of the four listed genes without indication of the regions that need to be conserved or the specific arrangement of the genes and promoters or terminators. One of skill in the art would conclude that the specification fails to disclose a representative number of species to describe the claimed genera while describing only the construct of SEQ ID NO: 5 in claim 15. In the broadest reasonable interpretation, claim 13 might be considered as potentially allowable if the consideration of 95% identity is taken out of the independent claim 1. Allowable Subject Matter Claim 15 is allowed. Conclusion Claims 1, 6-11, 13 and 16-19 are not allowed. Claim 15 is allowed. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ELLY GERALD STOICA whose telephone number is (571)272-9941. The examiner can normally be reached M-F 8-5 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Joanne Hama can be reached at 571-272-2911. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. ELLY-GERALD STOICA Primary Examiner Art Unit 1647 /Elly-Gerald Stoica/Primary Examiner, Art Unit 1647
Read full office action

Prosecution Timeline

Jan 08, 2025
Application Filed
Jun 16, 2026
Non-Final Rejection mailed — §112
Aug 19, 2026
Response Filed
Sep 17, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12734180
TREATMENT OF PROSTATE CANCER WITH A COMBINATION OF ABIRATERONE ACETATE AND NIRAPARIB
3y 10m to grant Granted Sep 15, 2026
Patent 12734225
PEPTIDE VACCINES
3y 4m to grant Granted Sep 15, 2026
Patent 12729236
HYDROPHILIC LINKERS FOR MULTIVALENT PEPTIDE CONJUGATES
4y 8m to grant Granted Sep 08, 2026
Patent 12721812
NOVEL TUMOR-SPECIFIC ANTIGENS FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) AND USES THEREOF
3y 11m to grant Granted Sep 01, 2026
Patent 12721905
COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR
3y 4m to grant Granted Sep 01, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
67%
Grant Probability
89%
With Interview (+22.5%)
2y 6m (~9m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1242 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month